Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. .
   PubMed Web of Science ®Google Scholar
• Izzo F, Piccirillo M, Albino V, et al. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8900 high‐risk patients. HPB. 2013;15(12):985–990.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Hepatocellular carcinoma (HCC); aetiological considerations. Adv Mod Oncol Res. 2015;1(1):18.
   Google Scholar
• Subramaniam S, Kelley RK, Venook AP. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013;2(4):33.
   PubMedGoogle Scholar
• Nault JC, de Reyniès A, Villanueva A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145(1):176–187.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Yun C, Poon R, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008 April;15(4):1001–1007.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012 Jan;262(1):43–58. DOI:10.1148/radiol.11110144
   PubMed Web of Science ®Google Scholar
• Cammà C, Cabibbo G, Petta S, et al. Cost‐effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology. 2013;57(3):1046–1054.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Elsayed Z. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci. 2013;58(12):3389–3396.
   PubMed Web of Science ®Google Scholar
• Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review. Expert Rev Anticancer Ther. 2014;15(2):165–182.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Venook AP. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep. 2008;10:199–205.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology and End Results Program. About the SEER Program. [cited 2016 June 25]. Available from: http://seer.cancer.gov/about
   Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
   Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1):33–38.
   Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
   PubMed Web of Science ®Google Scholar
• Liu JH, Chen PW, Asch SM, et al. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol. 2004;11(3):298–303.
   PubMed Web of Science ®Google Scholar
• Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg. 2008;195(6):829–836.
   PubMed Web of Science ®Google Scholar
• Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249(5):799–805.
   PubMed Web of Science ®Google Scholar
• Cosgrove DP, Reyes DK, Pawlik TM, et al. Open-label single-arm Phase II trial of sorafenib therapy with drug-eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: clinical results. Radiology. 2015;277(2):594–603.
   PubMed Web of Science ®Google Scholar
• Erhardt A, Kolligs F, Dollinger M, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer Chemother Pharmacol. 2014;74(5):947–954.
   PubMed Web of Science ®Google Scholar
• Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136(6):1458–1467.
   PubMed Web of Science ®Google Scholar
• Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol. 2014;66(4):704–710.
   PubMed Web of Science ®Google Scholar
• Hanna N, Sun M, Meyer CP, et al. Survival analyses of metastatic renal cancer patients treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J Clin Oncol. 2016;34:3267–3275.
   PubMed Web of Science ®Google Scholar
• Shien T, Nakamura K, Shibata T, et al. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol. 2012;42(10):970–973.
   PubMed Web of Science ®Google Scholar
• Ruiterkamp J, Voogd AC, Tjan-Heijnen VC, et al. SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation. BMC Surg. 2012;12:5.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Abdel-Rahman O, Salu I, et al. Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. Clin Transl Oncol. 2016. In press.
   Web of Science ®Google Scholar
• Okusaka T, Okada S, Ishii H, et al. Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology. 1997;44(13):251–257.
   PubMed Web of Science ®Google Scholar
• Couto OF, Dvorchik I, Carr BI. Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci. 2007;52(11):3285–3289.
   PubMed Web of Science ®Google Scholar